Aryeh Jason, a director at Ligand Pharmaceuticals Inc., has filed a notice to sell 202 shares of the company. The total value of this transaction is approximately $64,738, based on the current market conditions. This filing, submitted on October 30, 2026, is significant as it reflects ongoing insider trading activity within the pharmaceutical industry.

Background

Ligand Pharmaceuticals Inc. operates in the pharmaceutical preparations sector. The company is incorporated in Delaware and is publicly traded on the Nasdaq under the SEC file number 001-33093. The firm is known for its innovative approaches in drug development and has been active in various therapeutic areas.

What the Filing Says

The filing indicates that Aryeh Jason acquired the shares through an open market purchase on March 13, 2019. The notice states, "The nature of acquisition transaction was an Open Market Purchase." The filing also notes that there is nothing to report on securities sold in the past three months.

Impact

This sale may affect Ligand Pharmaceuticals' investor relations, as insider transactions can influence market perception. The pharmaceutical preparations sector is closely watched by investors, and such activities can lead to shifts in stock performance and investor confidence.

What's Next

The filing does not say what happens next.